Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
BBIO Analyst Ratings
Strong Buy
12 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BBIO Stock 12 Month Forecast
Average Price Target
$53.90
▲(54.44% Upside)
| Highest Price Target$95.00 | Average Price Target$53.90 | Lowest Price Target$37.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
Reiterated
02/28/25
Leerink Partners
Reiterated
02/24/25
Scotiabank
Reiterated
02/21/25
Cantor Fitzgerald
Reiterated
02/20/25
Citi
Reiterated
02/20/25
Wells Fargo
Reiterated
02/20/25
TD Cowen
Reiterated
02/20/25
Mizuho Securities
Reiterated
02/20/25
Piper Sandler
Reiterated
02/19/25
H.C. Wainwright
Reiterated
02/13/25
Evercore ISI
$50
Buy
43.27%
Upside
Reiterated
02/06/25
BridgeBio Pharma (BBIO) Receives a Buy from Evercore ISIWe’re starting with what we understand to be industry averages across most of these metrics but note that BBIO is obviously doing its best to differentiate from “average” on this front. Accordingly, we expect a relatively dynamic model in these early quarters. We believe the impressive 60% YoY growth demonstrated by PFE’s tafamidis franchise – leading to $5.45B in 2024 sales – carries additional positive readthrough to Attruby. Despite our still conservative estimates that also take into account competition and taf generic entry in late 2028, we are increasingly confident in the blockbuster potential of Attruby and see ample room for upside in our model. We continue to be highly intrigued by BBIO’s unique setup with a high-profile commercial launch (that’s off to a stellar start) and 3 distinct Ph3 readouts teed up over the next ~12 mos. Reiterate OP. Reach out for a copy of our model.
Oppenheimer
―
Hold
―
Reiterated
01/14/25
Oppenheimer Sticks to Its Hold Rating for BridgeBio Pharma (BBIO)
BMO Capital
$37
Hold
6.02%
Upside
Reiterated
01/14/25
BridgeBio Pharma: Balancing Promising Launch Metrics and Future Uncertainties with a Hold Rating
J.P. Morgan
―
Buy
―
Reiterated
01/13/25
Optimistic Buy Rating for BridgeBio Pharma Driven by Promising Outlook and Clinical Catalysts
Goldman Sachs
$50→$55
Buy
57.59%
Upside
Reiterated
11/25/24
BridgeBio Pharma (BBIO) PT Raised to $55 at Goldman SachsGoldman Sachs analyst Paul Choi raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $55.00 (from $50.00) while maintaining a Buy rating.
Best Analysts Covering BridgeBio Pharma
Which Analyst Should I Follow If I Want to Buy BBIO and Sell After:
1 Month
xxx
Success Rate
25/47 ratings generated profit
Average Return
+4.09%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.19% of your transactions generating a profit, with an average return of +4.09% per trade.
3 Months
xxx
Success Rate
12/21 ratings generated profit
Average Return
+9.71%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +9.71% per trade.
1 Year
Success Rate
13/16 ratings generated profit
Average Return
+30.95%
reiterated a buy rating 11 days ago
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +30.95% per trade.
2 Years
xxx
Success Rate
19/20 ratings generated profit
Average Return
+77.24%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 95.00% of your transactions generating a profit, with an average return of +77.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BBIO Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Strong Buy
23
29
25
20
10
Buy
14
12
10
14
20
Hold
3
6
4
5
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
40
47
39
39
32
Each month's total comprises the sum of three months' worth of ratings.
BBIO Financial Forecast
BBIO Stock Forecast FAQ
What is BBIO’s average 12-month price target, according to analysts?
Based on analyst ratings, BridgeBio Pharma Inc’s 12-month average price target is $53.90.
What is BBIO’s upside potential, based on the analysts’ average price target?
BridgeBio Pharma Inc has 54.44% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BBIO a Buy, Sell or Hold?
BridgeBio Pharma Inc has a consensus rating of Strong Buy which is based on 12 buy ratings, 2 hold ratings and 0 sell ratings.
What is BridgeBio Pharma Inc’s price target?
The average price target for BridgeBio Pharma Inc is $53.90. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $95.00 ,the lowest forecast is $37.00. The average price target represents 54.44% Increase from the current price of $34.9.
The highest analyst price target is $95.00 ,the lowest forecast is $37.00. The average price target represents 54.44% Increase from the current price of $34.9.
What do analysts say about BridgeBio Pharma Inc?
BridgeBio Pharma Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of BBIO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.